C.R. Bard, Inc. (NYSE:BCR) insider Timothy P. Collins sold 55,818 shares of C.R. Bard stock in a transaction dated Thursday, October 12th. The stock was sold at an average price of $322.03, for a total value of $17,975,070.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
C.R. Bard, Inc. (NYSE BCR) opened at 328.08 on Friday. The company has a market capitalization of $23.84 billion, a P/E ratio of 43.07 and a beta of 0.58. C.R. Bard, Inc. has a 52 week low of $203.63 and a 52 week high of $330.31. The company’s 50 day moving average price is $321.97 and its 200-day moving average price is $312.52.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.06. The company had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. C.R. Bard had a return on equity of 50.25% and a net margin of 14.75%. C.R. Bard’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the business earned $2.64 earnings per share. Equities research analysts expect that C.R. Bard, Inc. will post $11.84 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share. This represents a $1.04 annualized dividend and a yield of 0.32%. The ex-dividend date is Thursday, December 7th. C.R. Bard’s dividend payout ratio is currently 13.70%.
TRADEMARK VIOLATION WARNING: “C.R. Bard, Inc. (BCR) Insider Timothy P. Collins Sells 55,818 Shares” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.dispatchtribunal.com/2017/10/27/timothy-p-collins-sells-55818-shares-of-c-r-bard-inc-bcr-stock.html.
Several equities analysts have recently issued reports on the company. Needham & Company LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday. Jefferies Group LLC reissued a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Thursday, September 14th. BidaskClub lowered C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Zacks Investment Research lowered C.R. Bard from a “buy” rating to a “hold” rating in a research report on Tuesday, August 1st. Finally, BMO Capital Markets reissued a “hold” rating and issued a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $292.00.
A number of hedge funds have recently made changes to their positions in BCR. Mitsubishi UFJ Securities Holdings Co. Ltd. raised its position in C.R. Bard by 70.4% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock valued at $145,000 after acquiring an additional 190 shares in the last quarter. SRS Capital Advisors Inc. raised its position in C.R. Bard by 0.7% during the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock valued at $148,000 after acquiring an additional 4 shares in the last quarter. Parallel Advisors LLC raised its position in C.R. Bard by 283.8% during the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock valued at $153,000 after acquiring an additional 369 shares in the last quarter. Captrust Financial Advisors purchased a new position in C.R. Bard during the second quarter valued at approximately $192,000. Finally, Choate Investment Advisors purchased a new position in C.R. Bard during the second quarter valued at approximately $201,000. Institutional investors own 79.51% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.